GHK-Cu: What the Research Actually Shows
A naturally occurring copper-binding tripeptide first identified in human plasma over fifty years ago, with the strongest human clinical trial data of any peptide on this site, and one real, unresolved tension in the cancer-biology literature worth understanding before using it.
A Naturally Occurring Copper-Binding Tripeptide That Declines With Age
GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper) is a small, naturally occurring peptide first identified in human blood plasma in 1973, where it was found circulating at meaningfully higher levels in younger adults than older adults. Follow-up work identified its exact structure (glycine-histidine-lysine) and found that it readily binds copper(II) ions, proposing a role as a copper transport and delivery molecule at the cellular level. GHK-Cu is not a synthetic laboratory invention in the way most peptides on this site are, it is a naturally circulating human molecule whose levels appear to decline with age, and most of its documented biological activity, tissue remodeling, collagen production, and wound-related signaling, traces to that copper-binding, copper-delivery function.
Evidence Summary
A Fifty-Year-Old Discovery, a Real Human Trial, and an Unresolved Cancer-Biology Question
Discovery: A Tripeptide That Declines With Age in Human Plasma
Pickart L, Thaler MM. "Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver." Nature New Biology. 1973;243(124):85-87. PMID: 4349963. This is the original discovery paper: the researchers identified a small peptide in human blood plasma that supported the survival of normal liver cells in culture, and found that plasma from older adults had markedly less of this activity than plasma from younger adults. The same paper found the peptide also stimulated growth in a cultured liver cancer (hepatoma) cell line, a finding worth carrying forward honestly rather than omitting, since it's directly relevant to the cancer-biology question addressed later in this guide.
Human Plasma / Cell Culture Study, 1973 · Endpoint: Normal Liver Cell Survival and Hepatoma Cell Growth, Foundational DiscoveryMechanism: Copper Transport and Collagen Stimulation
Pickart L, Freedman JH, Loker WJ, et al. "Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells." Nature. 1980;288(5792):715-717. doi: 10.1038/288715a0. This study identified the tripeptide's structure as binding copper(II) with high affinity and proposed its primary biological role: shuttling copper into cells, where copper serves as a required cofactor for numerous enzymes involved in tissue repair. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. "Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+." FEBS Letters. 1988;238(2):343-346. PMID: 3169264. This study directly tested GHK-Cu (explicitly named as such) on cultured human fibroblasts and found it stimulated collagen production at very low, physiologically plausible concentrations, independent of any change in cell proliferation. Together, these two studies form the mechanistic backbone for GHK-Cu's use in tissue repair and skin applications: copper delivery enabling collagen-synthesis machinery that's otherwise copper-dependent.
In Vitro Fibroblast and Cell-Binding Studies · Endpoint: Copper Binding and Collagen Synthesis, Mechanistic, Not a Clinical OutcomeHuman Clinical Trial: Facial Wrinkles and Collagen
Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. "Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters." Journal of Aging Science. 2016;4(3):166. doi: 10.4172/2329-8847.1000166. This randomized, double-blind clinical trial used a split-face design in 40 women aged 40-65 (39 completed) comparing a GHK-Cu nano-carrier serum against a comparator peptide serum (Matrixyl 3000) and a control serum, applied twice daily for 8 weeks. GHK-Cu reduced wrinkle volume by 31.6% more than the comparator (p=0.004) and 55.8% more than control (p<0.001), and reduced wrinkle depth by 32.8% versus control (p=0.012). A companion in vitro portion of the same study, using cultured human dermal fibroblasts, found GHK-Cu increased both collagen and elastin secretion and shifted MMP/TIMP enzyme ratios in a direction favoring tissue preservation over breakdown. This is genuine randomized, controlled, human outcome data, not just a mechanism study, though it is limited to topical cosmetic use and a single research group's trial.
Human RCT, Split-Face Design (n=39 Completers) · Endpoint: Facial Wrinkle Volume/Depth at 8 Weeks, Randomized and Double-Blind, Topical Cosmetic Use OnlyAn Unresolved Question: Cancer Cell Growth vs. Anti-Cancer Gene Expression
Pickart L, Margolina A. "Modulation of Gene Expression in Human Breast Cancer MCF7 and Prostate Cancer PC3 Cells by the Human Copper-Binding Peptide GHK-Cu." OBM Genetics. 2021;5(2):128. doi: 10.21926/obm.genet.2102128. This paper reanalyzed public gene-expression data (the Broad Institute's Connectivity Map) to look at how GHK-Cu affects gene activity in cultured breast and prostate cancer cell lines, reporting upregulation of several apoptosis-related and tumor-suppressor genes. Taken alongside the original 1973 discovery paper's finding that the same tripeptide stimulated growth in a liver cancer cell line, this leaves a genuinely open question rather than a settled one: is GHK-Cu's relationship to cancer cell biology protective, permissive, or context-dependent on cell type and concentration? Both findings come from small, non-replicated studies, and the 2021 analysis is a computational reanalysis of existing data rather than a new wet-lab or clinical experiment, and comes from the same research lineage as the original discovery. Neither finding should be read as settling the question in either direction.
Cancer Cell Line Studies, Cell Culture (1973) and Bioinformatic Reanalysis (2021) · Endpoint: Cell Growth and Gene Expression in Cancer Cell Lines, Conflicting and UnreplicatedWhat the Research Doesn't Yet Show
No verifiable human or GHK-Cu-specific in vitro study supports the hair growth claims common in GHK-Cu marketing; the study sometimes cited for this could not be confirmed as testing GHK-Cu itself rather than a different copper tripeptide, so it isn't included here. No injectable or systemic human trial exists for GHK-Cu, every piece of controlled human evidence concerns topical, cosmetic use. And the cancer-biology question raised above is unresolved, not reassuring: one old cell-culture finding showed cancer cell growth stimulation, and one newer, non-replicated computational reanalysis reports the opposite. Neither result should be treated as the final word.
Investigational for clinical/therapeutic use; not FDA-approved as a drug for any indication. (GHK-Cu is a common cosmetic ingredient, which is a separate regulatory category from the therapeutic uses discussed on this page.)
How This Fits the Cellular Medicine Framework
GHK-Cu sits at the intersection of cell signaling and cellular metabolism in this framework: its core function is delivering copper, a required cofactor for multiple enzymes involved in tissue remodeling and antioxidant defense, into cells that need it. That's a genuinely well-supported piece of biochemistry, and it's why GHK-Cu has the strongest human trial data of any compound covered here. But the unresolved cancer-cell-growth question is a useful reminder that this framework's job is to explain mechanism, not to imply that a well-understood mechanism automatically means a fully understood safety profile in every tissue context. A molecule that reliably delivers a growth-supportive cofactor to cells is doing something real, and what that means for a specific cell type under specific conditions still has to be checked on its own terms rather than assumed favorable.
References
- Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology. 1973;243(124):85-87. PMID: 4349963
- Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717. doi:10.1038/288715a0 · PMID: 7453802
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. PMID: 3169264
- Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. J Aging Sci. 2016;4(3):166. doi:10.4172/2329-8847.1000166
- Pickart L, Margolina A. Modulation of Gene Expression in Human Breast Cancer MCF7 and Prostate Cancer PC3 Cells by the Human Copper-Binding Peptide GHK-Cu. OBM Genetics. 2021;5(2):128. doi:10.21926/obm.genet.2102128
Explore the Rest of the Knowledge Center
Hormones, Women's Health, Men's Health, Peptides, and Metabolic Health, five practical categories, one shared framework underneath all of them.